SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Shattuck Labs, Inc.
Date: Sept. 24, 2025 · CIK: 0001680367 · Accession: 0000000000-25-010405

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290355

Date
September 24, 2025
Author
Division of
Form
UPLOAD
Company
Shattuck Labs, Inc.

Letter

Re: Shattuck Labs, Inc. Registration Statement on Form S-3 Filed September 18, 2025 File No. 333-290355 Dear Taylor Schreiber:

September 24, 2025

Taylor Schreiber Chief Executive Officer Shattuck Labs, Inc. 500 W. 5th Street, Suite 1200 Austin, TX 78701

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Melanie E. Neary

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 24, 2025

Taylor Schreiber
Chief Executive Officer
Shattuck Labs, Inc.
500 W. 5th Street, Suite 1200
Austin, TX 78701

 Re: Shattuck Labs, Inc.
 Registration Statement on Form S-3
 Filed September 18, 2025
 File No. 333-290355
Dear Taylor Schreiber:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Melanie E. Neary
</TEXT>
</DOCUMENT>